Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2024

Lee Eun Ji, Oh Seung Yeon, Lee You Won, Kim Ju Young, Kim Min-Je, Kim Tae Ho, Lee Jii Bum, Hong Min Hee, Lim Sun Min, Baum Anke, Woelflingseder Lydia, Engelhardt Harald, Petronczki Mark, Solca Flavio, Yun Mi Ran, Cho Byoung Chul

Abstract excerpt

PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) serve as the standard first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC). Despite the sustained clinical benefits achieved through optimal EGFR-TKI treatments, including the third-generation EGFR-TKI osimertinib, resistance inevitably develops. Currently, there are no targeted therapeutic options available...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 38330145
DOI: 10.1158/1078-0432.CCR-23-2951

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.PMID 38330145Read ↗

JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.Semantic proximity Read ↗

Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC.Semantic proximity Read ↗

Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development.Semantic proximity Read ↗

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.Semantic proximity Read ↗

Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update.Semantic proximity Read ↗

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors.Semantic proximity Read ↗

HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.Semantic proximity Read ↗

CZC54252 overcomes Osimertinib resistance by targeting EGFRC797S mutations.Semantic proximity Read ↗

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.